FDA extends review of Praxis drug for rare epilepsy to December 2026
Go back to FDA extends review of Praxis drug for rare epilepsy to December 2026| (NASDAQ: PRAX) | Delayed: 351.81 -3.34 (0.94%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $355.15 | 52 Week High | $ | |||
| Open | $352.99 | 52 Week Low | $ | |||
| Day High | $357.50 | P/E | N/A | |||
| Day Low | $349.82 | EPS | $ | |||
| Volume | 175,356 | |||||
